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ABSTRACT 
 
An important factor in energy and nutrient pathways is the mammalian target of rapamycin 
complex 1 (mTORC1). The multiprotein complex, with the central component mTOR, regulates 
cell growth and survival. Mice with muscle-specific inactivation of mTORC1 die after 4-6 months 
of respiratory failure caused by a progressive myopathy. Next to structural changes, like fiber 
atrophy, the deficiency of mTORC1 in muscle also causes metabolic alterations. Muscles of 
mTORC1-deficient mice show a decrease in oxidative capacity and fatty acid metabolism, 
caused by a reduced transcription of several mitochondrial genes. This is due to a reduced 
transcription of the master regulator of mitochondrial biogenesis, PGC-1α. Interestingly, 
transgenic or pharmacological increase of PGC-1α levels restores mitochondrial function in mice 
with ablated mTORC1 activity, but does not prevent the myopathy. 
Additional metabolic changes in mTORC1-deficient muscle include glucose metabolism. Mice 
with inactivated mTORC1 in muscle show accumulations of glycogen, accompanied by a 
significant reduction of glucose uptake and glycolysis. The glycogen content is regulated through 
the activation of PKB/Akt, independently of PGC-1α. The reduction of glucose metabolism, in 
turn, correlates with an upregulation of the class II HDACs.  
Besides inefficient nutrient uptake, mice lacking muscle mTORC1 increase their energy 
expenditure, which might be due to an upregulation of UCPs. Together, these metabolic 
changes lead to a protection against diet-induced obesity and hepatic steatosis. Thus, the 
mTORC1 is a central hub of metabolic pathways in skeletal muscle affecting systemic energy 
homeostasis. 
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INTRODUCTION 
 
Rapamycin is a metabolite of the bacteria Streptomyces hygroscopicus, which were discovered 
in a soil sample from one of the Easter Islands in 1965 (Vezina et al., 1975). The compound was 
named after the small island Rapa Nui where the said sample was taken from. At first, 
rapamycin was only described for having an antifungal effect (Sehgal et al., 1975). However, the 
first description set in motion a cascade of events that resulted into an immunosuppressive drug 
that has been on the market for several years. The molecular target of rapamycin is a protein 
called TOR (target of rapamycin). It is a serine/threonine protein kinase and is evolutionary 
highly conserved from yeast to humans. Its mammalian counterpart is called mTOR (mammalian 
target of rapamycin) and can assemble into two distinct protein complexes (Wullschleger et al., 
2006). mTOR complex 1 (mTORC1) is rapamycin sensitive and is composed of mTOR, 
regulatory-associated protein of mTOR (raptor), mLST8 and the later identified partners PRAS40 
and DEPTOR (Figure 1) (Peterson et al., 2009; Thedieck et al., 2007). Originally, the second 
protein complex mTOR complex 2 (mTORC2) was described as rapamycin-insensitive, as acute 
treatment with rapamycin did not affect its activity. Yet, later studies have shown that in certain 
cell types chronic rapamycin exposure inhibits the new assembly of the complex, while not 
affecting pre-existing mTORC2 (Sarbassov et al., 2006). mTORC2 is formed out of mTOR, 
rapamycin-insensitive companion of mTOR (rictor), mLST8, DEPTOR, mSIN1 and protor1/2 
(Laplante and Sabatini, 2012). 
 
Substrates regulated by the mTOR complexes 
Initially, TOR in yeast was found to regulate cell size and later mTOR was discovered to also 
regulate growth in mammalian cells (Wullschleger et al., 2006). The physiological importance of 
mTOR became apparent by the fact that mice deficient for mTOR or raptor die shortly after 
implantation at E5.5-6.5 (Gangloff et al., 2004; Guertin et al., 2006; Murakami et al., 2004). 
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Similarly, mice deficient for mTORC2 activity by the knockout of rictor or mSIN1, also die 
embryonically but slightly later at E11.5 (Guertin et al., 2006; Jacinto et al., 2006; Shiota et al., 
2006). Next to the developmental importance, over the years the number of cellular processes 
dependent on mTOR signalling increased dramatically and it was discovered that the two mTOR 
complexes each signal via distinct effector pathways. mTORC1 is involved in protein synthesis, 
cell growth, autophagy, cell cycle progression and energy metabolism. mTORC2 is shown to 
affect mainly cytoskeletal organization and cell survival (Laplante and Sabatini, 2012).  
 
mTORC2 phosphorylates a key regulator of cell survival, Protein kinase B (PKB, also known as 
Akt), at the serine site S473 (Sarbassov et al., 2005). Phosphorylation of S473 stimulates 
PKB/Akt phosphorylation at the threonine residue T308 by phosphoinositide-dependent protein 
kinase-1 (PDK1) and results in full PKB/Akt activation. Two additional kinases regulated by 
mTORC2 are serum- and glucocorticoid-induced protein kinase 1 (SGK1) and protein kinase C 
α (PKCα) (Figure 1). SGK1 affects ion transport and growth in different cell lines (Garcia-
Martinez and Alessi, 2008). PKCα is known to control cytoskeletal organization by regulating 
actin dynamics in vitro (Sarbassov et al., 2004). However, so far the effect of mTORC2 on actin 
organization was not yet confirmed in vivo. 
 
The two best-characterized substrates of the mTORC1 are eIF4E-binding protein 1 (4E-BP1) 
and ribosomal protein S6 kinase (S6K). Both regulate mRNA translation, hence promote protein 
synthesis, and are directly phosphorylated by mTORC1 (Ma and Blenis, 2009). These two 
effectors are believed to be the principal pathway through which mTORC1 promotes growth in 
all cells. On top of translational regulation, S6K has a second crucial role in mTOR signaling. 
Constitutive activation of mTORC1 induces a negative feedback loop over S6K to attenuate 
phosphoinositide 3-kinase (PI3K) via inhibition of insulin receptor substrate 1 (IRS1) (Figure 1) 
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(Harrington et al., 2004). In particular, S6K was shown to directly phosphorylate IRS1 and 
indirectly also regulate its transcription (Um et al., 2004). 
 
 
Next to activating the translational regulators, mTORC1 also influences growth by inhibiting 
autophagy, the central degradation process in cells. In most cell types, mTORC1 directly 
phosphorylates and supresses a kinase complex called Ulk1/Atg13/FIP200, which is required to 
initiate autophagy (Hosokawa et al., 2009; Kim et al., 2011). Through this complex, mTORC1 
Figure 1. The mTOR signaling pathway. (Polak and Hall, 2009) 
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regulates the formation of autophagosomes that then engulf cytoplasmic proteins or organelles 
and fuse to lysosomes, leading to their degradation. 
Over the last decade several other targets of mTORC1 were discovered. Of particular interest is 
that mTORC1 controls mitochondrial gene expression and function (Schieke et al., 2006). 
Recent work demonstrates that mTORC1 interacts indirectly with the main mitochondrial gene 
regulator, peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) over the 
transcription factor yin-yang 1 (YY1) (Blattler et al., 2012b; Cunningham et al., 2007).  
 
Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) 
PGC-1α is the best characterized member of the PGC-1 family, which is composed of two 
additional members: PGC-1β and PGC-1 related coactivator (PRC) (Lin et al., 2005). PGC-1α is 
found in all mammals and was originally identified in brown adipose tissue (BAT) (Puigserver et 
al., 1998). In general, PGC-1α is highly expressed in tissues with high energy requirements like 
skeletal muscle, heart, liver, brain, pancreas, kidney and white adipose tissue (WAT). Across the 
different tissues, stressors such as exercise, cold or fasting are supposed to lead to PGC-1α 
activation (Handschin and Spiegelman, 2006). Its role is best studied in skeletal muscle, where 
PGC-1α was demonstrated to be highly expressed in oxidative slow-twitch (type I) muscles (Lin 
et al., 2002). PGC-1α was shown to be a transcriptional co-activator that controls different 
processes including mitochondrial biogenesis, skeletal muscle fiber-type determination, 
angiogenesis and fatty acid oxidation. Its most prominent role, however, is to regulate a large 
number of transcription factors, including, among other, PPARα, PPARγ, ERRα, NRF-1 and 2, 
GABP, TFAM, all implicated in mitochondrial biogenesis and oxidative phosphorylation 
(Fernandez-Marcos and Auwerx, 2011). 
 
Like mTOR, PGC-1α is thought to be a central integrator of external signals. It is known to be 
regulated on a transcriptional and a post-transcriptional level (Fernandez-Marcos and Auwerx, 
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2011). The PGC-1α promoter contains binding sites for MEF2, FOXO1, ATF2 and CREB. They 
are, in turn, modulated by different signaling pathways, such as insulin, cytokines, exercise, cold 
and glucagon. Post-transcriptionally, PGC-1α was demonstrated to be regulated by 
phosphorylation, acetylation, methylation and ubiquitination. AMPK and p38 MAPK are the best-
characterized protein kinases known to target PGC-1α (Jager et al., 2007; Puigserver et al., 
2001). An additional kinase which was shown to inhibit PGC-1α activity, is PKB/Akt, downstream 
of the insulin pathway (Li et al., 2007). Binding of PGC-1α to SIRT1 leads to its deacetylation 
and its subsequent activation (Canto et al., 2009). Silent information regulator 1 (SIRT1) is a 
newly discovered deacetylase that seems to play an important role in aging and cancer induction 
in mice (Gerhart-Hines et al., 2007). 
 
Regulation of the mTOR pathway 
One important function of mTORC1 is to sense growth factors to regulate cell growth (Polak and 
Hall, 2009). In particular, binding of insulin or insulin-like growth factors (IGFs) to their receptors 
leads to recruitment and phosphorylation of IRS-1 and activation of the PI3K signaling pathway 
(Figure 1) (Martin and Hall, 2005). At the cell membrane, PI3K controls the activity of PDK1, the 
kinase of PKB/Akt. Upon activation, PKB/Akt also translocates to the membrane where is gets 
phosphorylated and subsequently signals to mTORC1 as described below. Thus with regard to 
the ability of mTORC2 to phosphorylate PKB/Akt, PKB/Akt acts both up- and downstream of 
mTORC1. Activation of PKB/Akt triggers the inhibition of the tuberous sclerosis complex 1 
(TSC1) and tuberous sclerosis complex 2 (TSC2). Subsequently, the TSC1/TSC2 complex 
releases its inactivation of the small GTPase ras homolog enriched in brain (Rheb). Rheb is a 
direct activator of mTORC1 (Figure 1) (Inoki et al., 2003; Long et al., 2005). Next to inhibition of 
the TSC complex, PKB/Akt also regulates mTORC1 in a TSC-independent manner. In response 
to growth factors, PKB/Akt inhibits Proline-rich Akt substrate 40kDa (PRAS40) by 
phosphorylating it. PRAS40, in turn, binds raptor and thereby directly inhibits the mTORC1 
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(Sancak et al., 2007; Thedieck et al., 2007). Besides insulin and IGF-1, the energy state of a cell 
also influences mTOR activity. Cells with low energy levels show a high AMP/ATP ratio. This 
activates the adenosine monophosphate-activated protein kinase (AMPK). AMPK influences 
mTORC1 activity in two different ways. First, it can phosphorylate TSC2 which results in an 
increase of its GAP activity towards Rheb, thus inhibiting mTORC1 (Inoki et al., 2003). Secondly, 
it directly inhibits mTORC1 by the phosphorylation of raptor (Figure 1) (Sancak et al., 2008).  
Amino acids were identified to stimulate the kinase activity of mTORC1 over the Rag GTPases 
(Figure 1). The Rag proteins do not directly regulate mTORC1 activity, but seem to promote the 
intracellular localization of mTOR to a compartment that also contains its activator Rheb (Sancak 
et al., 2008). 
 
mTORC1 signaling in skeletal muscle 
Skeletal muscle is an organ in which cell size is highly dynamic and of key importance for its 
function. The size of a muscle adapts rapidly in response to external stimuli, age or pathological 
situations. To elucidate the function of the mTOR pathway specifically in skeletal muscle several 
transgenic mouse lines have been developed over the last few years. The two most important 
publications focusing on the mTOR pathway in skeletal muscle used the Cre-loxP recombination 
system. LoxP sites were either introduced into the mTOR or the rptor locus, respectively, and 
the mice carrying these floxed genes were crossed with mice transgenically expressing Cre 
under the human skeleton actin (HSA) promotor. HSA is specifically expressed in myotubes and 
has a temporal expression onset just after myotube fusion (Schwander et al., 2003). Therefore, 
skeletal muscle-specific knockout mice for mTOR (Risson et al., 2009) or raptor (called RAmKO 
mice, Bentzinger et al., 2008, see appendix) were obtained upon such a breeding scheme. Both 
transgenic mouse lines are undistinguishable from their control littermates at birth but suffer from 
progressive atrophy and die after 4-6 months. Next to the myopathy both mouse models with 
skeletal muscle-specific inactivation of mTORC1 show different metabolic changes in their 
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muscles. The oxidative capacity is dramatically impaired and they accumulate significant 
amounts of glycogen. 
 
The goal of this study is to further characterize mTORC1 signaling in skeletal muscle. In a recent 
publication we could show that the reduced oxidative capacity in different mouse models with 
inactivated mTORC1 is due to the reduced transcription of PGC-1α (see publication 1). In a 
second part, we analyzed the systemic metabolic changes that result from the specific 
inactivation of mTORC1 in skeletal muscle (see publication 2). Finally, in order to solve the open 
question of the premature death of RAmKO mice we carried out metabolic analysis of their blood 
(see additional findings). In addition to the confirmation of the importance of mTORC1 in muscle 
physiology, this work reveals interesting new details on the role of muscle mTORC1 in 
mitochondrial activity and whole body metabolism. 
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SUMMARY 
The mammalian target of rapamycin complex 1 (mTORC1) is a central node in a complex net of 
signaling pathways that are involved in growth and survival of cells. The serine/threonine protein 
kinase integrates external signals and affects different nutrient pathways. Here we show that in 
skeletal muscle, inactivation of mTORC1 reduces diet-induced obesity and protects from hepatic 
steatosis. Mice with a muscle-specific inactivation of mTORC1 have increased energy 
expenditure, probably due to an upregulation of the uncoupling proteins. In addition to the 
elevated calorie consumption, the mice have a reduced transcription of fatty acid and glucose 
metabolism-regulating genes. The inefficient fatty acid metabolism is caused by a mitochondrial 
dysfunction mediated by reduced PGC-1α levels. Additionally, we demonstrate that skeletal 
muscle mTORC1 regulates HDAC4/5, which is the likely mediator of glucose uptake and 
glycolysis. Taken together, the mTORC1 is a central regulator of metabolic pathways in skeletal 
muscle and in addition affects systemic energy homeostasis. 
 
 
 
 
Keywords: skeletal muscle; mTORC1; energy expenditure; HDAC, UCP 
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INTRODUCTION 
The highly conserved serine/threonine protein kinase mammalian target of rapamycin (mTOR) is 
known to control numerous cellular processes related to cell growth (Wullschleger et al., 2006). 
mTOR can form two functionally distinct multiprotein complexes, the rapamycin-sensitive 
mTORC1, and mTORC2, which is only sensitive to prolonged rapamycin treatment (Sarbassov 
et al., 2006). mTORC1 is a central sensor of growth factors and nutrients in various cell types 
and was described to play an important role in different disease models like cancer, metabolic 
diseases and aging (Laplante and Sabatini, 2012). Thus, the interest on the mTOR pathway is 
growing extensively, especially with regard to type 2 diabetes and the obesity epidemic (Polak 
and Hall, 2009). mTORC1 is highly active in the liver and skeletal muscle of obese and high-fat-
fed rodents (Khamzina et al., 2005; Um et al., 2004). Inhibition of mTOR signaling has been 
proposed to mimic calorie restriction, which is metabolically highly beneficial and extents lifespan 
(Selman et al., 2009). Paradoxically, prolonged treatment with the mTORC1-inhibitor rapamycin 
causes glucose intolerance and insulin resistance (Cunningham et al., 2007; Fraenkel et al., 
2008; Houde et al., 2010). However, recent work demonstrates that the insulin resistance 
caused by chronic rapamycin treatment seems to be the result of the inactivation of mTORC2 
and not mTORC1 and that this impact is uncoupled from the beneficial systemic effects of 
mTORC1 inhibition (Lamming et al., 2012). 
It is difficult to distinguish the contribution of different tissues on the systemic effects of 
rapamycin treatment. To address this question, various mouse models with tissue-specific 
deletions of essential components of the mTORC1 were generated over the last years (Laplante 
and Sabatini, 2012). White adipose tissue (WAT)-specific deletion of raptor, a component 
essential for the activity of mTORC1, leads to improved insulin sensitivity and reduced adipocyte 
number and size (Polak et al., 2008). Inactivation of mTORC1 in the liver leads to resistance to 
hepatic steatosis and hypercholesteremia induced by a Western diet (Peterson et al., 2011). 
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Loss of functional mTORC1 in skeletal muscle leads to a progressive muscle atrophy and an 
early death (Bentzinger et al., 2008; Risson et al., 2009). In addition, mTORC1 deficiency in 
skeletal muscle causes a variety of tissue-specific metabolic changes. mTORC1 activity in 
muscle is necessary for the formation of a functional complex of YY1 with PGC-1α and by this 
means regulates PGC-1α levels itself and mitochondrial gene expression (Blattler et al., 2012b; 
Cunningham et al., 2007). Due to reduced PGC-1α levels, the oxidative capacity of mTORC1-
deficient muscle is severely impaired (Romanino et al., 2011). Inactivation of mTORC1 in 
skeletal muscle also causes elevated levels of glycogen due to an increase of glycogen 
synthesis and a decrease of glycogen degradation (Bentzinger et al., 2008; Romanino et al., 
2011). 
Glucose uptake of peripheral tissue is an important factor in type 2 diabetes and skeletal muscle 
is a major site of glucose uptake in response to food intake and insulin. In this study we show 
that skeletal muscle mTORC1 regulates systemic energy homeostasis and that both fatty acid 
(FA) and glucose metabolism are dependent on proper mTORC1 signaling in skeletal muscle. In 
particular, we provide evidence that inactivation of mTORC1 in skeletal muscle leads to an 
upregulation of class II histone deacetylases (HDACs), correlating with a downregulation of 
glycolytic genes and a decrease of the glucose uptake.  
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RESULTS 
 
Inactivation of mTORC1 in skeletal muscle reduces diet-induced obesity and protects 
from hepatic steatosis. 
Mice with muscle-specific knock out of rptor (called RAmKO mice) suffer from a strongly reduced 
body weight, due to muscle atrophy that is accompanied by reduced weight of the epididymal fat 
pads (Bentzinger et al., 2008). To investigate whether the phenotype of RAmKO mice can be 
ameliorated by increased calorie intake, we fed the mice a high-fat (HFD) or a high-carbohydrate 
diet (HCD). After 14 weeks, the difference in body weight between RAmKO and control (ctrl) 
mice became apparent (Figure 1A, B and Table S1). Ctrl mice gained weight on a HCD and 
became severely obese on a HFD, whereas RAmKO mice were completely resistant to diet-
induced obesity. Interestingly, the effect of muscle-specific inactivation of mTORC1 also affected 
other tissues than skeletal muscle itself. HFD induced an enlarged and paler liver in ctrl mice 
that was due to an accumulation of lipids (hepatic steatosis). In contrast, the liver of RAmKO 
mice which were on a HFD for the same time period showed a normal size and coloration 
(Figure 1C and Table S1). In contrast to the ctrls, liver sections stained with Oil Red O 
demonstrated no accumulation of lipids in RAmKO mice fed a HFD (Figure 1D). The inability to 
accumulate lipids and gain weight can be the result of altered feeding behavior or nutrient 
absorption. We analyzed the food intake of the RAmKO mice and found it to be unchanged 
(Figure 1E). Also the ability of the body to take up nutrients, as assessed by quantifying the 
amount of lipids in the feces, was not altered (Figure 1F). Because the activity of the RAmKO 
mice is strongly reduced due to their myopathic phenotype (Bentzinger et al., 2008), activity 
cannot be responsible for their leanness either. Using indirect calorimetry we investigated the 
energy expenditure of ctrl and RAmKO mice and found that the calorie consumption was 
significantly elevated in the latter (Figure 1G). The effect can be observed both in the dark and 
the light phase, again suggesting that the activity of the mice is not relevant. Together, these 
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results show that due to higher energy consumption RAmKO mice are resistant to diet-induced 
obesity and hepatic steatosis. 
 
There is no shift in substrate utilization in RAmKO mice but fatty acid and glucose 
metabolism are reduced. 
Oxygen and carbohydrate level measurements showed no difference of the respiratory 
exchange ratio (RER) of RAmKO compared to ctrl mice (Figure 2A). Hence, RAmKO mice show 
no change in the preference of either carbohydrates or fat as an energy source. This was 
unexpected, because RAmKO muscle has a reduced oxidative capacity and contains increased 
glycogen levels (Bentzinger et al., 2008), both indications of a shift in nutrient utilization. 
Interestingly, transcript levels of genes important for the transport of FA and β-oxidation were all 
significantly lower in RAmKO mice compared to ctrl littermates (Figure 2B). Because both 
processes take place in the mitochondria, this is likely due to the reduced number of 
mitochondria in RAmKO mice caused by PGC-1α reduction (Romanino et al., 2011). RAmKO 
muscle also expressed lower levels of glucose transporters (GLUT1 and GLUT4) and other 
glucose metabolism genes (Figure 2C). This confirms that there is no shift in substrate utilization 
in skeletal muscle after mTORC1 inactivation, but both FA and glucose metabolism are reduced. 
The fact that the levels of glucose transporters are reduced explains why the uptake of glucose 
is impaired in RAmKO mice as seen by a shift in the glucose tolerance curve (GTT) in our 
previous publication (Bentzinger et al., 2008). Fasting blood glucose levels were not significantly 
changed, but tended to be lower in RAmKO mice than ctrl mice (Figure 2D). However, compared 
to ctrl littermates, RAmKO mice exhibited significantly lower circulating insulin concentrations 
(Figure 2E). To directly assess whether the RAmKO mice are responsive to insulin, we carried 
out an insulin tolerance test (ITT) (Figure 2F). RAmKO mice showed a slightly delayed response 
to insulin, reflecting the reduced uptake of glucose in skeletal muscle.  
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The substantial effect of skeletal muscle-specific inactivation of mTORC1 on global energy 
homeostasis raises the question whether signaling in other metabolically active tissues, such as 
the liver, is also affected. Therefore, we analyzed the transcription of genes important for FA and 
glucose metabolism in the liver of the RAmKO mice. In both cases no changes in mRNA levels 
could be observed compared to ctrl animals (Figure S1A and S1B). In addition, the levels of two 
important metabolic regulators in the liver, PGC-1α and HNF4α were also unchanged (Figure 
S1C). In summary, our data show that glycogen storage and glucose usage are differentially 
regulated in muscles of RAmKO mice. Additionally, compared to ctrls there is no metabolic shift 
in mTORC1-inactivated skeletal muscle but both, glycolytic and FA oxidizing genes are 
significantly downregulated and there is no compensatory mechanism in the liver. 
 
Skeletal muscle mTORC1 regulates HDAC4/5 and uncoupling proteins 
Glycogen storage, glucose uptake and glycolysis are differentially regulated by mTORC1. The 
increase of the glycogen synthesis in RAmKO muscle is due to the hyperactivation of Akt/PKB 
and its target glycogen synthase kinase 3β (GSK3β) (Bentzinger et al., 2008). However, the 
reduced glucose uptake and glycolysis must have another mechanism, because activation of 
Akt/PKB in skeletal muscle has been shown to upregulate glycolytic proteins (Izumiya et al., 
2008). Several alternative pathways have been described to regulate glycolytic proteins. In vitro 
mTORC1 has been shown to activate glucose uptake and glycolysis over the hypoxia-inducible 
factor-1α (HIF-1α) (Duvel et al., 2010). However, HIF-1α does not seem to be responsible for the 
reduction of the glycolytic proteins in skeletal muscle, as its protein level and prolyl hydroxylation 
were unchanged in RAmKO mice (Figure S2A). Next to HIF-1α, the class II histone 
deacetylases 4 and 5 (HDAC 4 and 5) were described to regulate glycolytic proteins in skeletal 
muscle (McGee et al., 2008; Tang et al., 2009). Indeed, the protein levels of HDAC 4 and 5 were 
upregulated in RAmKO mice (Figure 3A and quantification in Table S2). Secondly, Dach2 which 
is known to be inhibited by HDAC4 and 5 in skeletal muscle was reduced (Figure 3B), confirming 
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the increased activity of the HDACs. Dach2 is an inhibitor of myogenin, which was strongly 
upregulated in RAmKO mice (Figure 3C). It is well described that the HDACs and its 
downstream targets are regulated through activity and innervation (Moresi et al., 2010; Tang and 
Goldman, 2006). Especially in denervated muscle the HDAC-Dach2-myogenin signaling 
pathway has been shown to be differently regulated (Cohen et al., 2007). Interestingly, in 
RAmKO mice we could observe ectopic clusters in the diaphragm (Bentzinger et al., 2008) and 
an upregulation of acetylcholine receptor αand γ (AChRα, γ) in the soleus muscle (Figure S2B 
and S2C), all signs of destabilization of the neuromuscular junctions (NMJs).  
Even though the HDACs are the likely cause of the downregulation of glycolytic genes in 
RAmKO muscle, the increased energy expenditure in RAmKO mice remains unexplained. 
Uncoupling proteins (UCPs) are key factors in the regulation of energy expenditure (Azzu and 
Brand, 2010). Through uncoupling of the proton gradient in the inner membrane of the 
mitochondria, the UCPs regulate the efficiency of ATP production and therefore the energy 
expenditure. mTORC1 has previously been described to regulate the UCPs in WAT (Polak et al., 
2008). Therefore we decided to investigate the levels of UCPs in RAmKO mice. The levels of 
ubiquitously expressed UCP2 and the muscle-specific UCP3 were both increased in RAmKO 
muscle, as shown by qRT-PCR (Figure 3D) and western blot (Figure 3E and quantification in 
Table S2). The effect of skeletal muscle mTORC1 on energy expenditure again seems to be 
muscle-specific, as the UCPs in liver, white and brown adipose tissue (BAT) were not 
significantly increased (Figure S2D and S2E). Taken together, our data show that the decrease 
of the glycolytic genes correlates to an increase of HDAC4 and 5, and that like in the WAT, 
mTORC1 regulates the UCPs and energy expenditure. 
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DISCUSSION 
The control of energy balance plays a central role in metabolic diseases such as type 2 diabetes 
and obesity. mTORC1 has been postulated to play an essential role in glucose homeostasis by 
fine tuning the insulin signaling and by controlling metabolic pathways in different tissues 
(Tremblay et al., 2005; Um et al., 2006). Skeletal muscle is a particularly important player in the 
regulation of energy balance in the body. Here we show that inactivation of mTORC1 in skeletal 
muscle reduces glucose uptake and glycolysis. Previous work has shown that glycogen stores 
are significantly increased in mTORC1-deficient muscle (Bentzinger et al., 2008). Our data thus 
show that glucose uptake and glycolysis and glycogen storage are regulated by distinct 
pathways. 
 
Similar to RAmKO mice, treatment with the mTORC1-inhibitor rapamycin leads to a reduced 
glucose uptake (Blattler et al., 2012a). However, rapamycin-treated mice become insulin 
resistant, whereas RAmKO mice are insulin tolerant. Treatment with rapamycin affects several 
metabolically active tissues simultaneously and reduces mTOR signaling in skeletal muscle and 
in the liver (Blattler et al., 2012a). We could not observe differences in key metabolic signaling 
pathways in the liver of RAmKO mice. After rapamycin treatment in both skeletal muscle and in 
the liver PKB/Akt activity is reduced (Blattler et al., 2012a). In RAmKO mice a strong activation 
of PKB/Akt is observed, because of the inhibitory feedback loop of S6K (Bentzinger et al., 2008). 
This results in increased levels of IRS-1 and activation of the insulin pathway. Intriguingly, 
RAmKO mice are protected from metabolic effects of rapamycin on glucose tolerance (Blattler et 
al., 2012a). This suggests that the activation state of the insulin pathway and PKB/Akt 
determines whether the mice are susceptible to the development of diabetes or not.  
 
RAmKO mice display a reduction in glycolytic proteins that coincides with the increase in class II 
HDACs. Although HDACs have been described to regulate the transcription of glycolytic 
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proteins, in skeletal muscle they have mostly been implicated in denervation signaling (Cohen et 
al., 2007). Denervation upregulates HDACs and through inhibition of Dach2 it activates the 
transcription of myogenin. The transcription of Dach2 and myogenin in RAmKO mice is 
significantly altered, confirming changes in HDAC activity. In addition, as indicated by the 
upregulation of the α and γ subunits of the AChR, RAmKO mice show signs of NMJ 
destabilization. Nevertheless, the overall morphology of the NMJ is not severely disturbed 
(Bentzinger et al., 2008). The underlying cause of the mild NMJ destabilization observed in 
RAmKO mice remains to be determined. Taken together, our study reveals that mTORC1 and 
class II HDACs regulate glycolytic proteins and glucose uptake in skeletal muscle, resulting in 
mild effect on glucose tolerance.  
 
Next to a reduction of glucose metabolism, inactivation of mTORC1 also leads to a reduced 
transcription of FA metabolism genes. This phenotype is paralleled by a reduction of the 
oxidative capacity of the muscles and by a reduction of the number of mitochondria. Therefore, it 
is most likely due to the lower levels of PGC-1α in RAmKO muscle. These results suggest that 
by controlling FA and glucose metabolism, glycogen storage and the oxidative capacity, 
mTORC1 is a central controller of metabolic properties of muscle tissue. Moreover, since both 
FA oxidation and glucose metabolism are decreased in RAmKO mice, inactivation of mTORC1 
does not cause a preference for utilization of a particular nutrient. 
 
Similar to adipose tissue, deletion of raptor in skeletal muscle leads to an upregulation of UCPs 
and thereby probably increases the energy expenditure of the RAmKO mice. Unlike the adipose-
specific knockout of raptor (Polak et al., 2008), in RAmKO mice uncoupling proteins in the other 
metabolically active tissues are not affected. Similar to RAmKO mice, mice overexpressing 
human UCP3 are hyperphagic but lean, show reduced weight gain upon HFD and display 
significantly higher total oxygen consumption compared to ctrl littermates (Clapham et al., 2000). 
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Nevertheless, it is not completely clear if the regulation of UCP2 and UCP3 directly correlates 
with UCP1 regulation. It is debated whether UCP2 and UCP3 need an additional activation 
signal to be fully functional, since mice in which UCP2 or UCP3 are knocked out show only weak 
phenotypes (Brand and Esteves, 2005; Harper and Himms-Hagen, 2001).  
 
Here we show that skeletal muscle mTORC1 plays an essential role in whole body homeostasis 
and energy expenditure. mTORC1 controls the major metabolic pathways in skeletal muscle. 
Both FA and glucose metabolism are impaired in RAmKO mice and the expression of UCPs is 
increased. The inefficient nutrient utilization and the increased energy demand lead to beneficial 
systemic effects and to a resistance to diet-induced obesity. Our work is first to analyze the 
systemic metabolic consequences of mTORC1 inhibition specifically in skeletal muscle. 
Moreover, our data demonstrates that muscle mTORC1 is a significant controller of systemic 
energy demand and implies that the beneficial effects of rapamycin on systemic metabolism and 
longevity could be due to inhibition of mTORC1 in skeletal muscle. 
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EXPERIMENTAL PROCEDURES 
 
Animals and Diet Treatments 
RAmKO mice (described earlier (Bentzinger et al., 2008)) carry floxed alleles for rptor and 
express the Cre recombinase under the control of the muscle-specific human skeletal actin 
(HSA) promoter. The animals were maintained in a conventional facility with a fixed light cycle. 
Food intake and body weight were measured weekly. Four weeks after weaning RAmKO and 
ctrl mice were fed a HFD (60% fat, 20% protein, and 20% carbohydrates, Research Diets), HCD 
(10% fat, 20% protein, and 70% carbohydrates, Research Diets) or normal chow (Kliba Nafag) 
for 14 weeks. Studies were carried out according to criteria outlined for the care and use of 
laboratory animals and with approval of the authorities. 
 
Histology 
Livers frozen in liquid nitrogen-cooled isopentane were cut into 10 µm cross-sections. Sections 
were stained with hematoxylin (Merck) and Oil Red-O (Sigma‐Aldrich) and mounted with glycerol 
gelatin (Sigma‐Aldrich). 
 
Indirect Calorimetry 
Mice were acclimatized for two days (individual housing) followed by data acquisition over three 
days. Oxygen use and carbon dioxide production was measured and energy expenditure was 
calculated with the Weir equation. Respiratory exchange ratio (RER) was calculated as VCO2/ 
VO2. Data were normalized to body weight. 
 
Metabolic Measurements 
The amount of lipids in feces was determined by collecting feces over 24 hrs and then a 
standard methanol:chloroform extraction. Blood glucose was measured directly from the tail vein 
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with the OneTouch UltraMini glucometer (LifeScan). Plasma Insulin amount was determined 
according to the manufacturer’s instruction with the ultra-sensitive mouse insulin ELISA kit 
(Crystal Chem).  
 
IP Insulin Tolerance Test (ITT)  
The mice were fasted for 6 hrs and 0.5 mU/g insulin was injected. Basal blood glucose was 
measured before the injection and at the indicated time points after intraperitoneal injection.  
 
Quantitative Real-time PCR 
Total RNA was isolated (SV Total RNA isolation System, Promega) and equal amounts of RNA 
reverse transcribed using a mixture of oligodT and random hexamer primers (iScript cDNA 
Synthesis Kit, Bio-Rad). Quantitative real-time PCR was performed using SYBR Green (Power 
SYBR Green Master Mix, Applied Biosystems) and StepOneTM Software 2.1. (Applied 
Biosystems). Expression levels for each gene of interest were normalized to the mean cycle 
number using real-time PCR for the housekeeping protein β-actin. All experiments were 
performed in triplicates and the following primers were used:  
 
CD36 fw: TGGCCTTACTTGGGATTGG bw: CCAGTGTATATGTAGGCTCATCCA 
FATP1 fw: GGCTCCTGGAGCAGGAACA bw: ACGGAAGTCCCAGAAACCA 
FATP4 fw: GGCTTCCCTGGTGTACTATGGAT bw: ACGATGTTTCCTGCTGAGTGGTA 
FABPpm fw: AGCGGCTGACCAAGGAGTT bw: GACCCCTGCCACGGAGAT 
FABP3 fw: CCCCTCAGCTCAGCACCA bw: CAGAAAAATCCCAACCCAAGAAT 
CPT-1b fw: GGTCGATTGCATCCAGAGAT bw: GACTCCGGTGGAGAAGATGA 
MTE-1 fw: TGGGAACACCATCTCCTACAA bw: CCACGACATCCAAGAGACCA 
GLUT 1 fw: CGAGGGACAGCCGATGTG bw: TGCCGACCCTCTTCTTTCAT 
GLUT 4 fw: GATGAGAAACGGAAGTTGGAGAGA bw: GCACCACTGCGATGATCAGA 
HK2 fw: CCCTGCCACCAGACGAAA bw: GACTTGAACCCCTTAGTCCATGA 
PK fw: CGATCTGTGGAGATGCTGAA bw: AATGGGATCAGATGCAAAGC 
PFK fw: CAGATCAGTGCCAACATAACCAA bw: CGGGATGCAGAGCTCATCA 
LDHA fw: TGTCTCCAGCAAAGACTACTGT bw: GACTGTACTTGACAATGTTGGGA 
Dach2 fw: ACTGAAAGTGGCTTTGGATAA bw: TTCAGACGCTTTTGCATTGTA 
Myogenin fw: TGGGCGTGTAAGGTGTGTAA bw: GGCCTCATTCACCTTCTTGA 
UCP2 fw: ACCAAGGGCTCAGAGCATGCA bw: TGGCTTTCAGGAGAGTATCTTTG 
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UCP3 fw: ACTCCAGCGTCGCCATCAGGATTCT bw: TAAACAGGTGAGACTCCAGCAACTT 
β-actin fw: CAGCTTCTTTGCAGCTCCTT bw: GCAGCGATATCGTCATCCA 
 
Western Blotting 
Western blots were performed as described earlier (Bentzinger et al., 2008) using following 
antibodies: HDAC4 from Santa Cruz Biotechnology, HDAC5 from Cell Signaling, UCP2 from 
Millipore, UCP3 from Abcam and α-actinin from Sigma. The concentrations used were according 
to the manufacturer and to determine total protein levels a reducing agent compatible BCA 
Protein Assay (Pierce) was used. Quantifications were performed with the ImageJ software. 
Grey values were corrected for background. 
 
Statistical Analysis 
Compiled data are expressed as mean ± SD. For statistical comparisons the Student’s t-test was 
used. The level of significance is indicated as follows: *** p<0.001, ** p< 0.01, * p< 0.05. 
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Figure 1. RAmKO mice are resistant to diet-induced obesity and hepatic steatosis due to 
increased energy expenditure 
(A) Raptor muscle-knockout (RAmKO) and control (ctrl) mice were reared with a normal chow 
diet, high-fat diet (HFD) or a high-carbohydrate diet (HCD) starting at the age of 6 weeks. 
Animals were weighed weekly. Starting at the age of 6 weeks, RAmKO mice weigh significantly 
less than ctrl mice on all three diets (n=5-8).  
(B) Representative photograph showing mice that were on a HFD for 100 days. RAmKO mice 
compared to ctrl littermates clearly do not show the dramatic increase of body weight due to the 
diet. 
(C) Picture shows representative livers of mice after 100 days on HFD. Muscle deficiency of 
raptor protects from HFD-induced hepatic steatosis, which is characterized by an enlarged liver 
containing a high number of vacuoles filled with triglycerides. 
(D) Cross-sections of livers from mice that were on a HFD for 100 days stained with Oil Red O 
and hematoxylin. The red color is indicative for the lipid content in the tissue. Ctrl mice suffer 
from an accumulation of lipids after a HFD, RAmKO mice do not. Scale bar = 50 µm. 
(E) Average daily food intake of normal chow measured over 100 days. Food intake of RAmKO 
mice is not changed compared to ctrl littermates. Data are normalized to body weight (n=5-8). 
(F) Lipid absorption in the digestive system was measured by methanol:chloroform extraction in 
feces, that was collected over 24 hrs. No difference was found between RAmKO and ctrl mice. 
Weight of the extracted lipids is given as percentage of the total weight. Mice were around 12 
weeks old (n=4-7). 
(G) Energy expenditure measured by indirect calorimetry. Data are normalized to body weight. 
RAmKO mice burn in average 7% more calories. The difference is larger in the light phase when 
ctrl and RAmKO mice are less active. Mice were around 12 weeks old (n=8). 
Values in E-G represent mean ± SD. p values are *p < 0.05, **p < 0.01, ***p < 0.001.  
 
RESULTS – Publication 2 
42 
 
 
RESULTS – Publication 2 
43 
Figure 2. RAmKO mice show a reduction of fatty acid and glucose metabolism 
(A) Respiratory exchange ratio (RER) measured by indirect calorimetry. Both in the light and the 
dark phase RAmKO and ctrl mice have the same turnover of oxygen to carbon dioxide, 
indicating that the mice metabolize the same fuel sources to supply the body with energy. Mice 
were around 12 weeks old (n=8). 
(B) Relative mRNA levels of the indicated genes controlling fatty acid (FA) metabolism in soleus 
muscle of 12-week-old mice determined by qRT-PCR. RAmKO mice show a reduction in the 
mRNA levels of genes controlling FA uptake: CD36 (also known as fatty acid translocase), fatty 
acid transport protein 1 and 4 (FATP1, FATP4), plasma membrane-associated fatty acid binding 
protein (FABPpm). Gene controlling FA binding: fatty acid binding protein 3 (FABP3). Genes 
responsible for the activation of FA for β-oxidation: carnitine palmitoyltransferase 1 (CPT-1b) 
and mitochondrial thioesterase (MTE-1) (n=3-5). 
(C) Relative mRNA levels of the indicated genes controlling glucose metabolism in soleus 
muscle of 12-week-old mice determined by qRT-PCR. RAmKO mice have lower mRNA levels of 
genes controlling glucose uptake: glucose transporter 1 and 4 (GLUT 1, 4) and several glycolytic 
genes: hexokinase 2 (HK2), pyruvate kinase (PK), phosphofructokinase (PFK), lactate 
dehydrogenase A (LDHA) (n=5-6). 
(D) Blood glucose concentration after overnight fasting of 9-week-old RAmKO mice and control 
littermates. Glucose levels are unchanged in RAmKO mice, but have a tendency to be lower 
(n=8-11). 
(E) Insulin concentration in the blood of 12-week-old RAmKO mice and control littermates. 
Insulin levels are slightly reduced in RAmKO mice (n=4-5).  
(F) Insulin tolerance test (ITT). RAmKO mice are mildly insulin resistant (n=4-5). 
Values in A-F represent mean ± SD. p values are *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 3. HDACs and UCPs are upregulated in RAmKO mice 
(A) Representative western blot of soleus muscle lysates from 12-week-old mice using 
antibodies directed against the proteins indicated. The levels of histone deacetylases 4 and 5 
(HDAC4, HDAC5) are elevated in RAmKO muscles. Equal amount of protein was loaded in each 
lane. An antibody against α-actinin was used as loading control. For quantification see 
Supplemental Table 1 (n=4-5). 
(B, C) Relative mRNA levels of the HDAC targets, Dach2 and myogenin, in soleus muscle of 12-
week-old mice as determined by qRT-PCR (n=5-6). 
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(D) Relative mRNA levels of the indicated genes in soleus muscle of 12-week-old mice as 
determined by qRT-PCR. The uncoupling proteins 2 and 3 (UCP2, UCP3) show a higher 
expression in the muscle of RAmKO mice (n=3-4). 
(E) Representative western blot of soleus muscle lysates from 12-week-old mice using 
antibodies directed against the proteins indicated. The levels of the uncoupling proteins are 
elevated in RAmKO muscles. Equal amount of protein was loaded in each lane. An antibody 
against α-actinin was used as loading control. For quantification see Supplemental Table 1 (n=4-
5). 
Values in B, C and D represent mean ± SD. p values are *p < 0.05, **p < 0.01, ***p < 0.001.  
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Supplemental Data 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Quantitative Real-time PCR 
Expression levels for each gene of interest were normalized to the mean cycle number using 
real-time PCR for the different housekeeping proteins. β-actin was used for the skeletal muscle 
and the liver samples. For the WAT polymerase (RNA) II polypeptide A (PolR2a) and for the 
BAT TATA Box binding protein (TBP) was used as a housekeeper. Following primers were 
used: 
PPARα fw: TGTTTGTGGCTGCTATAATTTGC bw: GCAACTTCTCAATGTAGCCTATGTTT 
Mttp fw: CGTCCACATACAGCCTTGAC bw: CCACCTGACTACCATGAAGC 
CPT1a fw: GGAGAGAATTTCATCCACTTCCA bw: CTTCCCAAAGCGGTGTGAGT 
Dgat1 fw: CATGCGTGATTATTGCATCC bw: ACAGGTTGACATCCCGGTAG 
MCAD fw: TTTCGAAGACGTCAGAGTGC bw: TGCGACTGTAGGTCTGGTTC 
ACC-1 fw: ACCTTACTGCCATCCCATGTG bw: GTGCCTGATGATCGACGAACAAA 
SCD1 fw: CAAGCTGGAGTACGTCTGGA bw: CAGAGCGCTGGTCATGTAGT 
GLUT1 fw: CGAGGGACAGCCGATGTG bw: TGCCGACCCTCTTCTTTCAT 
GLUT2 fw: GTCCAGAAAGCCCCAGATACC bw: GTGACATCCTCAGTTCCTCTTAG 
GK fw: CCCTGAGTGGCTTACAGTTC bw: ACGGATGTGAGTGTTGAAGC 
G6Pase fw: CAGAATGGGTCCACCTTGACAC bw: AGCGGAATGGGAGCAACTTG 
PEPCK fw: GCATAACTAACCCGAAGGCAAG bw: CATCCAGGCAATGTCATCGC 
PGC-1α fw: TGATGTGAATGACTTGGATACAGACA bw: GCTCATTGTTGTACTGGTTGGATATG 
HNF4α fw: CCTGCAGGTTTAGCCGACAAT bw: ATCCGGTCCCGCTCATTTT 
AChR fw: AACGAGACTCGGATGTGGTC bw: GTCGCACCACTGCATCTCTA 
AChR fw: CGTCTGGTGGCAAAGCT bw: CCGCTCTCCATGAAGTT 
UCP1 fw: CGACTCAGTCCAAGAGTACTTCTCTTC bw: GCCGGCTGAGATCTTGTTTC 
UCP2 fw: TCCCCTGTTGATGTGGTCAA bw: CAGTGACCTGCGCTGTGGTA 
PolR2a fw: AATCCGCATCATGAACAGTG bw: CAGCATGTTGGACTCAATGC 
TBP fw: TGCTGTTGGTGATTGTTGGT bw: CTGGCTTGTGTGGGAAAGAT 
 
Antibodies 
HIF-1α and Hydroxy-HIF-1α (Pro564) from Cell Signaling were used for western blot. 
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Figure S1.  
(A) Relative mRNA levels of the indicated genes controlling fatty acid (FA) metabolism in liver of 
12-week-old mice determined by qRT-PCR. FA metabolism is not changed in the liver of 
RAmKO mice. The following transcripts were analyzed: peroxisome proliferator-activated 
receptor α (PPARα), microsomal triglyceride transfer protein (Mttp), carnitine 
palmitoyltransferase I (CPT1a), diglyceride acyltransferase 1 (Dgat1), medium-chain acyl-CoA 
dehydrogenase (MCAD), acetyl-CoA carboxylase 1 (ACC1), stearoyl-CoA desaturase-1 (SCD1) 
(n=4-6). 
(B) Relative mRNA levels of the indicated genes controlling glucose metabolism in liver of 12-
week-old mice as determined by qRT-PCR. Transcription of glycolytic genes is not changed in 
the liver of RAmKO mice. The following transcripts were analyzed: glucose transporter 1 and 2 
(GLUT 1, 2), glucokinase, glucose-6-phosphatase (G6Pase), phosphoenolpyruvate 
carboxykinase (PEPCK) (n=4-6). 
(C) Relative mRNA levels of the main regulator of mitochondrial biogenesis, PPARγ coactivator-
1α (PGC-1α), and a liver specific regulator of lipid transport and glucose metabolism, hepatocyte 
nuclear factor 4α (HNF-4α), in liver of 12-week-old mice as determined by qRT-PCR (n=4-6). 
All mice for the liver analysis were starved overnight and half of them were refed for 4 hrs. All 
values represent mean ± SD. p values are *p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure S2.  
(A) Representative western blot of soleus muscle lysates from 12-week-old mice using 
antibodies directed against the proteins indicated. The levels of hypoxia-inducible factor-1α (HIF-
1α) and its hydroxylated form Hydroxy-HIF-1α are unchanged in RAmKO muscles. Equal 
amount of protein was loaded in each lane. An antibody against α-actinin was used as loading 
control.  
(B, C) Relative mRNA levels of acetylcholine receptor α and γ (AChRα, γ) in soleus muscle of 
12-weeks-old mice determined by qRT-PCR (n=3-4). 
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(D) Relative mRNA levels of UCP2 in liver and white adipose tissue (WAT) of 12-weeks-old mice 
determined by qRT-PCR. Mice were starved overnight and half of them were refed for 4 hrs 
(liver: n=7-9, WAT: n=2-4). 
(E) Relative mRNA levels of UCP1 and 2 in brown adipose tissue (BAT) of 12-weeks-old mice 
determined by qRT-PCR (n=4-5). 
All values represent mean ± SD. p values are *p < 0.05, **p < 0.01, ***p < 0.001.  
 
 
 
 
Table S1.  
Body weight and weight of different organs of ctrl and RAmKO mice after 100 days on HFD 
(n=3-5). 
All values represent mean ± SD. p values are *p < 0.05, **p < 0.01, ***p < 0.001. 
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Table S2.  
Quantification of Western blot analysis of soleus muscle lysates from 12-week-old mice for the 
proteins indicated. Numbers given represent average grey value  SD after subtraction of the 
background. p values are *p < 0.05, **p < 0.01, ***p < 0.001. 
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Additional Findings 
 
Although RAmKO mice have better metabolic parameters, such as a resistance to diet-induced 
obesity, they still die at an age of 17-27 weeks. There are several possibilities for the cause of 
this early death. RAmKO mice suffer from progressive muscle atrophy in all muscles including 
the diaphragm (Bentzinger et al., 2008). Atrophy of the diaphragm and the intercostal muscles 
could eventually lead to insufficient respiration and therefore cause premature death. 
Nevertheless, other reasons like kidney failure cannot be excluded. In fact, a very common 
complication in patients suffering from metabolic myopathies, like McArdle’s disease, is kidney 
failure. In damaged skeletal muscle specific proteins, like creatine kinase, can enter into the 
bloodstream via the disrupted muscle membrane (Warren et al., 2002). The kidneys normally 
clear the blood from excessive proteins, but too high levels can lead to renal failure. To elucidate 
the cause of death we therefore did extensive blood analysis of the RAmKO mice. 
 
RAmKO mice die of respiratory failure caused by progressive muscle atrophy 
Analysis of RAmKO mice showed that 9-week-old mice have unchanged blood pH, however 
after 20 weeks the pH is significantly lowered (Table 1). A possible explanation is metabolic 
acidosis which is caused by kidney failure. As mentioned above, kidney failure in RAmKO mice 
would eventually be caused by to high creatine kinase levels in the blood due to muscle 
damage. In general, renal acidosis is associated with an accumulation of creatinine in the blood. 
Therefore, we checked both creatine kinase and creatinine levels in the blood of RAmKO mice 
(Table 1). Both parameters were unchanged, therefore we can exclude that the RAmKO mice 
suffer from inefficient kidney function. Interestingly, the observation that the incorporation of the 
Evans blue dye into muscle fibers of RAmKO mice is not increased as in other muscle 
dystrophies confirms that the muscle damage in RAmKO mice is not as severe as in other 
myopathies (Bentzinger et al., 2008).  
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A second type of acidosis is the so-called respiratory acidosis, caused by a build-up of carbon 
dioxide in the blood due to hypoventilation. Indeed, 20-week-old RAmKO mice show a significant 
increase of the carbon dioxide in the blood. The finding is accompanied by lower blood oxygen 
levels at the same age (Table 1), suggesting insufficient respiration. The fact that also for the 
blood gases we only see significant changes in the older mice highlights that the acidosis is 
coupled to the progressive muscle atrophy observed in the RAmKO mice. 
In conclusion, old RAmKO mice suffer from hypoxia caused by muscle atrophy. The progression 
of the atrophy leads to impaired respiration and an early death. 
 
Methods and Materials 
Blood was taken from the tail vein and pH and blood gases were determined by the i-STAT 
system (Abbott) (n=6-7). The analysis of creatinine and creatine kinase clearance from the blood 
was done by the Universitätsspital Basel (n=4-6). 
 
9-week-old 20-weeks-old
control RAmKO control RAmKO
pO2 [mm Hg] 82.8 ±16.3 97.3 ±17.1 90.7 ±7.2 68.7 ±5.6***
pCO2 [mm Hg] 18.5 ±5.8 16.4 ±4.0 18.5 ±2.3 32.8 ±8.2**
creatinine [umol/L] - - 9.5 ±1.0 7.3 ±3.6
creatine kinase [U/L] - - 102.3 ±60.7 93.5 ±19.8
pH 7.51 ±0.06 7.56 ±0.07 7.55 ±0.07 7.45 ±0.05*
 
Table 1. Blood analysis of RAmKO and control mice at different ages. Values represent mean ± 
SD. p values are *p < 0.05, **p < 0.01, ***p < 0.001. 
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CONCLUDING REMARKS 
Loss of muscle mass and the regulation of whole body metabolism by the muscle are major 
components of several diseases including cancer, metabolic diseases and aging. Thus, it is of 
fundamental importance to improve the understanding of the molecular mechanisms and the 
signaling pathways that control muscle size and function but also the metabolic pathways 
regulating skeletal muscle physiology. This work demonstrates that mTORC1 controls the 
central metabolic pathways in skeletal muscle. Inactivation of muscle mTORC1 leads to a lethal 
myopathy, reduction of mitochondrial function and changes in glucose metabolism.  
 
In this study we attempted to dissect the role of the different pathways that are influenced by 
mTORC1 in skeletal muscle. By assembling in a complex with YY1 and PGC-1α mTORC1 
regulates mitochondrial number and activity. We could confirm that the changes in the oxidative 
capacity caused by mTORC1 inactivation can be rescued by the increase of PGC-1α levels 
(Publication 1). Moreover, the reduced mitochondrial activity also leads to a downregulation of 
FA metabolism genes and β-oxidation (Publication 2). Interestingly, the myopathy seems 
unaffected when PGC-1α levels are restored. In addition, PGC-1α seems not to play a role in the 
dramatic increase in glycogen content observed after mTORC1 inactivation in muscle. More 
likely, the increased glycogen content is regulated through the hyperactivation of PKB/Akt due to 
the loss of the inhibitory feedback loop from S6K on IRS-1. Other parts of glucose metabolism, 
namely glucose uptake and glycolysis, are independent of PKB/Akt activation in mTORC1-
deficient muscle. The expression of these glycolytic genes are probably reduced due to the 
upregulation of HDAC4 and 5 and result in a mild effect on glucose tolerance (Publication 2 and 
Bentzinger et al., 2008, see appendix). 
 
Further striking is the fact that we do not observe a classical fiber-type switch in the muscles of 
RAmKO mice. mTORC1 inactivation leads to structural changes in the muscle fibers such as an 
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upregulation of slow myosin heavy chain and other proteins typical for slow-twitch (type I) fibers 
(Bentzinger et al., 2008, see appendix). Additionally, the contractile properties show a shift 
towards slow twitch fiber type, as time to peak and relaxation time of the twitch are increased 
(Bentzinger et al., 2008, see appendix). From a metabolical point of view, the properties of 
mTORC1-inactivated muscle fibers look very different. The reduction of glycolytic proteins would 
fit to the fiber-type shift towards slow twitch muscles, but the RAmKO mice also show an 
increase in glycogen storage and a reduction of mitochondria and the oxidative capacity, arguing 
that the shift would go in the opposite direction, namely towards fast-twitch (type II) muscle 
fibers. Hence, we can conclude that mTORC1 regulates several fiber type-specific structural and 
metabolic properties from muscle fibers, but that there is no shift in substrate utilization. In 
addition, our results imply that the different fiber-type properties are partially regulated 
independently from each other. 
 
With this work we show that skeletal muscle mTORC1 plays a crucial role in whole body 
homeostasis and energy expenditure. When mTORC1 activity is reduced in muscle, the low 
nutrient utilization, coupled to increased energy demand, lead to beneficial systemic effects and 
to a resistance to diet-induced obesity. 
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